Holen Sie sich die Stockscreener-App
142.00
0.79%
1.11
Handel nachbörslich:
142.00
Schlusskurs vom Vortag:
$140.89
Offen:
$141.86
24-Stunden-Volumen:
981.33K
Relative Volume:
1.14
Marktkapitalisierung:
$14.08B
Einnahmen:
$2.41B
Nettoeinkommen (Verlust:
$305.80M
KGV:
48.14
EPS:
2.95
Netto-Cashflow:
$492.20M
1W Leistung:
-2.22%
1M Leistung:
+3.77%
6M Leistung:
+24.07%
1J Leistung:
+22.49%
1-Tages-Spanne:
$139.90
$142.08
1-Wochen-Bereich:
$139.90
$148.00
52-Wochen-Spanne:
$84.23
$154.61
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Vergleichen Sie NBIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
142.00 | 13.97B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
143.50 | 62.55B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.74 | 46.27B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
8.82 | 38.87B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.34 | 21.06B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
432.66 | 19.24B | 2.99B | 1.21B | 1.13B | 25.06 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Should You be Optimistic on Neurocrine Biosciences (NBIX)? - Yahoo Finance
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Atle Fund Management AB Raises Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Leerink Partners Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating - 富途牛牛
Neurocrine Biosciences (NBIX): Assessing Valuation After Promising Phase 2 Depression Trial Results - simplywall.st
Neurocrine details Phase 2 results for depression drug - Endpoints News
Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden - WV News
Neurocrine’s Phase II MDD success raises analyst spirits - Yahoo Finance
Avanza Fonder AB Sells 9,207 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Given "Outperform" Rating at Wedbush - MarketBeat
2,651 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by Fulton Bank N.A. - MarketBeat
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $163 to $188 - 富途牛牛
Neurocrine Bio. stock price target raised to $169 by Jefferies - Investing.com
Neurocrine’s depression drug shows significant improvement in phase 2 trial - Investing.com India
Neurocrine’s depression drug shows significant improvement in phase 2 trial By Investing.com - Investing.com South Africa
Pallas Capital Advisors LLC Increases Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Bio. stock holds steady as BMO reiterates Market Perform rating - Investing.com Canada
Neurocrine Bio. stock rating reiterated by Stifel on positive MDD data - Investing.com
Neurocrine Reports Positive Data From Phase 2 Study Of Osavampator - Nasdaq
Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder - PR Newswire
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
UBS reiterates Buy rating on Neurocrine Bio. stock with $188 target - Investing.com Canada
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Financiere des Professionnels Fonds d investissement inc. Purchases New Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences authorizes $500M share repurchase program - MSN
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Voya Investment Management LLC - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by First Hawaiian Bank - MarketBeat
Swedbank AB Has $63.29 Million Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
EPS Watch: Is Neurocrine Biosciences Inc forming a breakout pattern2025 Technical Overview & Free Fast Gain Swing Trade Alerts - خودرو بانک
Exploring High Growth Tech Stocks In The US Market September 2025 - simplywall.st
Market Review: Should I trade or invest in Neurocrine Biosciences IncWeekly Trade Review & Reliable Momentum Entry Alerts - خودرو بانک
Aug Spikes: Does Neurocrine Biosciences Inc have pricing powerMarket Weekly Review & Risk Controlled Stock Pick Alerts - خودرو بانک
Integrated Wealth Concepts LLC Boosts Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences’ SWOT analysis: stock outlook amid pipeline progress, IRA challenges - Investing.com Canada
Neurocrine Biosciences CFO Matt Abernethy sells $115,908 in stock - MSN
Neurocrine Biosciences chief scientific officer sells $336,238 in stock - MSN
Neurocrine Biosciences, Inc. $NBIX Holdings Trimmed by Plato Investment Management Ltd - MarketBeat
Fed Watch: Why is Neurocrine Biosciences Inc stock going upJuly 2025 Highlights & Reliable Volume Spike Alerts - خودرو بانک
Vident Advisory LLC Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Woodline Partners LP Buys Shares of 132,892 Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine to present new phase 2 data for depression treatment - Investing.com India
Neurocrine Biosciences, Inc. $NBIX Shares Bought by Swedbank AB - MarketBeat
Neurocrine to present new phase 2 data for depression treatment By Investing.com - Investing.com South Africa
Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025 - WV News
Neurocrine Biosciences to Present New Data From Phase 2 Study of Osavampator in Adults With Major Depressive Disorder at 38th Annual Psych Congress 2025 - 富途牛牛
Neurocrine upgraded at RBC Capital Markets on recent selloff - MSN
What Does Wall Street Think About Neurocrine Biosciences (NBIX)? - Yahoo Finance
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):